Page header

Position of the Transparency Council – mexiletine

At its meeting on 18 November 2024, the Transparency Council adopted position No. 126/2024 on the appropriateness of issuing approvals for reimbursement of the medicinal product mexiletine in multiple indications

 

Publication of the position >>